# EDGAR Filing Document

**Accession Number:** 0002006815
**File Stem:** 0000000000-26-001416
**Filing Date:** 2026-2
**Character Count:** 4619
**Document Hash:** e902d7a0b4b40ceacf4a6d6afe665b9b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-26-001416.hdr.sgml**: 20260528

**ACCESSION NUMBER**: 0000000000-26-001416

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20260211

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Voyager Acquisition Corp./Cayman Islands
- **CENTRAL INDEX KEY:** 0002006815
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 333-289108

**BUSINESS ADDRESS:**
- **STREET 1:** C/O WINSTON & STRAWN LLP
- **STREET 2:** 800 CAPITOL ST., STE 2400
- **CITY:** HOUSTON
- **STATE:** TX
- **ZIP:** 77002
- **BUSINESS PHONE:** 03477204333

**MAIL ADDRESS:**
- **STREET 1:** C/O WINSTON & STRAWN LLP
- **STREET 2:** 800 CAPITOL ST., STE 2400
- **CITY:** HOUSTON
- **STATE:** TX
- **ZIP:** 77002
**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Veraxa Biotech AG
- **CENTRAL INDEX KEY:** 0002079364
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** V8
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 333-289108

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** TALACKER 35
- **CITY:** ZURICH
- **PROVINCE COUNTRY:** V8
- **ZIP:** 8001
- **BUSINESS PHONE:** 41443858450

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** TALACKER 35
- **CITY:** ZURICH
- **PROVINCE COUNTRY:** V8
- **ZIP:** 8001
**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Veraxa Biotech Holding AG
- **CENTRAL INDEX KEY:** 0002079109
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** V8
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 333-289108

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** TALACKER 35
- **CITY:** ZURICH
- **PROVINCE COUNTRY:** V8
- **ZIP:** 8001
- **BUSINESS PHONE:** 41443858450

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** TALACKER 35
- **CITY:** ZURICH
- **PROVINCE COUNTRY:** V8
- **ZIP:** 8001
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001829126-25-005620

## Text-Extract

```

                                                            February 11, 2026

Christoph Antz
Chief Executive Officer
Veraxa Biotech Holding AG
Talacker 35
8001 Zurich, Switzerland

Adeel Rouf
Chief Executive Officer
Voyager Acquisition Corp./Cayman Islands
131 Concord Street
Brooklyn, NY 11201

       Re: Veraxa Biotech Holding AG
           Amendment No. 4 to Registration Statement on Form F-4
           Filed February 3, 2026
           File No. 333-289108
Dear Christoph Antz and Adeel Rouf:

     We have reviewed your amended registration statement and have the
following
comment.

       Please respond to this letter by amending your registration statement
and providing the
requested information. If you do not believe a comment applies to your facts
and circumstances
or do not believe an amendment is appropriate, please tell us why in your
response.

       After reviewing any amendment to your registration statement and the
information you
provide in response to this letter, we may have additional comments.

Amendment No. 4 to Registration Statement on Form F-4
Risk Factors, page 79

1.     We note your disclosure relating to the High Trail Financing Agreement
and the Lincoln
       Park Financing Agreement. Please include risk factor disclosure relating
to the fact that
       the notes are secured by all of your assets and the potential dilution
that may result from
       the equity purchase facility.
 February 11, 2026
Page 2

       Please contact Tara Harkins at 202-551-3639 or Kevin Vaughn at
202-551-3494 if you
have questions regarding comments on the financial statements and related
matters. Please
contact Tyler Howes at 202-551-3370 or Chris Edwards at 202-551-6761 with any
other
questions.

                                                        Sincerely,

                                                        Division of Corporation
Finance
                                                        Office of Life Sciences
cc:   Andrew Tucker, Esq.
      Michael J. Blankenship, Esq.

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._